Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec;6(12):731-3.
doi: 10.1038/nrclinonc.2009.168.

More is less -- combining targeted therapies in metastatic colorectal cancer

Cornelis J A Punt  1 , Jolien Tol
Affiliations
Review

More is less -- combining targeted therapies in metastatic colorectal cancer

Cornelis J A Punt et al. Nat Rev Clin Oncol. 2009 Dec.

Abstract

Targeted agents directed at VEGF, such as bevacizumab, and EGFR, such as cetuximab and panitumumab, have become part of the standard treatment of metastatic colorectal cancer. Only a subset of patients seem to benefit from such treatment, and varying results have been observed when different lines of treatment are used in combination with different cytotoxic drugs. Preclinical and early clinical data have shown promising results for the combination of anti-VEGF and anti-EGFR treatment. However, two recent phase III trials, CAIRO2 and PACCE, have shown a detrimental effect of adding an anti-EGFR antibody to standard chemotherapy plus bevacizumab. We discuss issues that may explain these unexpected results.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Oncol. 2007 Apr 20;25(12):1539-44 - PubMed
    1. J Clin Oncol. 2008 Apr 1;26(10):1626-34 - PubMed
    1. Ann Oncol. 2008 Apr;19(4):734-8 - PubMed
    1. J Clin Oncol. 2009 Feb 10;27(5):672-80 - PubMed
    1. N Engl J Med. 2009 Apr 2;360(14):1408-17 - PubMed

MeSH terms